Alumis Inc. Reports Positive 52-Week Data for ESK-001, a Next-Generation TYK2 Inhibitor for Moderate-to-Severe Plaque Psoriasis

Alumis announced positive Phase 2 OLE results for ESK-001, a TYK2 inhibitor for moderate-to-severe plaque psoriasis, showing sustained clinical improvements. https://www.nasdaq.com/articles/alumis-inc-reports-positive-52-week-data-esk-001-next-generation-tyk2-inhibitor-moderate